Pfizer-BioNTech COVID vaccine candidate induces robust immun
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The vaccine candidate, BNT162b1— co-developed by the pharmaceutical giant Pfizer and the German biotech company BioNTech —"elicited a robust immune response in participants, which increased with dose level and with a second dose," according to a news release from the journal Nature, which published the trial data on Aug. 12.

BNT162b1, based on cutting-edge RNA gene technology, which helps kick-start the body's immune response when it encounters the new coronavirus.

Results of Phase 1/2 study :

~ Vaccine elicited a robust immune response in participants, and the higher the dose, the stronger the response, the authors reported.

~ Getting a second "booster" shot also upped the immune system response.

~ Levels of [coronavirus-] neutralizing antibodies were 1.9 to 4.6 times higher than those in patients recovering from SARS-CoV-2.

~ Phase 3 trials are needed to confirm the safety, strength and duration of any protective effect.

~ The shot was "generally well-tolerated," although some recipients did have some transitory side effects such as soreness at the injection site, fatigue, headache, fever and sleep woes; which tended to clear up within a week of vaccination, the researchers said.

Source: https://www.nature.com/articles/s41586-020-2639-4
Dr. T●●●●z H●●●●●●i and 2 other likes this1 share
Like
Comment
Share